Publication:
Clinical outcome of rhabdomyosarcoma in adolescent and adult patients: Single center experience from Turkey

dc.contributor.authorsUstuner, Zeki; Basaran, Mert; Dizdar, Yavuz; Agaoglu, Fulya Yaman; Bilgic, Bilge; Sakar, Burak; Basaran, Gul Atalay; Darendeliler, Emin; Ozger, Harzem; Onat, Haluk; Bavbek, Sevil
dc.date.accessioned2022-03-14T09:11:07Z
dc.date.accessioned2026-01-11T06:03:33Z
dc.date.available2022-03-14T09:11:07Z
dc.date.issued2007
dc.description.abstractUSTUNER, Z., BASARAN, M., DIZDAR, Y., AGAOGLu, F.Y., BILGic, B., SAKAR, B., BASARAN, G.A., DARENDELILER, E., OZGER, H., ONAT, H. and BAVBEK, S. Clinical Outcome of Rhadomyosarcoma in Adolescent and Adult Patients: Single Center Experience from Turkey. Tohoku J. Exp. Med., 2007, 213 (3), 221-229 - Rhabdomyosarcoma (RMS) is rare disease in adults (age >= 16 years). The data from randomized prospective trials are scarce; the clinical outcome of these patients seems poor with the currently available treatment strategies. In this study, we report a single institution's experience in the treatment of adult RMS. We reviewed the medical records of patients with RMS who were >= 16 years and have been treated in our institution between 1988 and 2003 retrospectively. We analyzed the survival outcome of these patients and the prognostic impact of clinical/ pathological factors on their survival. In total, 23 patients with RMS were identified. Median age was 26 years (range, 16-72 years). Majority of patients were male (n: 17, 73.9%), and had large tumors ( >= 5 cm, n: 13, 56.5%), localized disease (NO, MO, n: 12, 52.2%), and embryonal histology (n: 10, 43.5%). Median overall survival was 31.3 months, and the 3-year progress ion-free survival and overall survival rates were 19.9% and 34.94%, respectively. Patients with smaller tumors (< 5 cm) (p < 0.04), local disease (p < 0.01), and normal lactic dehydrogenase (LDH) level (p < 0.01) at the time of diagnosis were found to have better survival outcome. The tumor size, serum LDH level, and metastatic disease at the time of diagnosis are potential predictors of outcome in patients with adult RMS. Adult RMS is an aggressive disease with poor survival despite treatment. The data from prospective, randomized multicenter trials are necessary in order to improve the clinical outcome of adult RMS patients. - rhabdomyosarcoma; adult; lactic dehydrogenase; survival; adolescent (0 2007 Tohoku University Medical Press
dc.identifier.doi10.1620/tjem.213.221
dc.identifier.eissn1349-3329
dc.identifier.issn0040-8727
dc.identifier.pubmed17984619
dc.identifier.urihttps://hdl.handle.net/11424/242725
dc.identifier.wosWOS:000250847300004
dc.language.isoeng
dc.publisherTOHOKU UNIV MEDICAL PRESS
dc.relation.ispartofTOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHIGH-DOSE CHEMOTHERAPY
dc.subjectSOFT-TISSUE SARCOMA
dc.subjectINTERGROUP RHABDOMYOSARCOMA
dc.subjectSTAGING SYSTEM
dc.subjectSURVIVAL
dc.subjectCHILDREN
dc.subjectAGE
dc.subjectIV
dc.titleClinical outcome of rhabdomyosarcoma in adolescent and adult patients: Single center experience from Turkey
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage229
oaire.citation.issue3
oaire.citation.startPage221
oaire.citation.titleTOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
oaire.citation.volume213

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
file.pdf
Size:
268.34 KB
Format:
Adobe Portable Document Format